StockTipsArenaBeta

BUY Zydus Lifesciences Limited — Chandan Taparia, Motilal Oswal

BUYZydus Lifesciences Limited
Zydus Lifesciences share price target & all analyst calls

byChandan Taparia, Motilal OswalHorizon: NA (inferred Intraday)8 Jul 2026, 9:24 am ISTvia NDTV Profit (Live)

Entry₹1,174Inferred
Target₹1,200
Total upside +2.21% (call closed)
Stop loss₹1,145-2.47% risk
Exit₹1,1458 Jul 2026, 2:42 pm
Stop-loss hit-2.47%
Follow Chandan Taparia for new calls(14% target hit, 64 closed calls)Get alertsWatch ZYDUSLIFE for new buy/sell callsGet alerts

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 3 Oct, 5:56 pm IST
2 supporting0 opposing
Supports the BUY call (2)

Zydus Lifesciences Limited has signed an MoU with Apollo Hospitals to expand access to the Shield Multi-Cancer Detection test (MCD) in India.

NSE · Press Release·3 Jul · 5d ago

(opens in new tab)

Zydus Lifesciences Ltd. has signed a Memorandum of Understanding (MoU) with Apollo Hospitals to expand access to the Shield™ Multi-Cancer Detection test (MCD) in India. This test screens for 10 common

BSE · Company Update·3 Jul · 5d ago

(opens in new tab)
Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Zydus Lifesciences

All analyst calls on Zydus Lifesciences

More from Chandan Taparia, Motilal Oswal

Every call and its outcome